Susquehanna International Group, LLP Arcellx, Inc. Call Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$50.91 - $86.61 $51 Million - $86.8 Million	1,001,900 Added 3063.91%	1,034,600 $86.4 Million
Q2 2024 Aug 15, 2024	SELL	$49.74 - $66.98 $1.37 Million - $1.84 Million	-27,500 Reduced 45.68%	32,700 $1.8 Million
Q1 2024 May 07, 2024	SELL	$51.85 - $73.49 $1.94 Million - $2.76 Million	-37,500 Reduced 38.38%	60,200 $4.19 Million
Q4 2023 Feb 14, 2024	BUY	$31.75 - $57.99 $2.82 Million - $5.16 Million	88,900 Added 1010.23%	97,700 $5.42 Million
Q3 2023 Nov 14, 2023	SELL	$31.51 - $37.4 $463,197 - $549,780	-14,700 Reduced 62.55%	8,800 $315,000
Q2 2023 Aug 11, 2023	BUY	$27.49 - $46.9 $646,015 - $1.1 Million	23,500 New	23,500 $743,000
Q4 2022 Feb 14, 2023	BUY	$17.18 - $33.0 $113,388 - $217,800	6,600 Added 47.48%	20,500 $635,000
Q3 2022 Nov 14, 2022	BUY	$16.67 - $22.04 $231,713 - $306,356	13,900 New	13,900 $261,000

205

44.2M

2.23M

907K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.85B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.